WO2019078177A1 - ニコチンアミドモノヌクレオチドを含む化粧品組成物 - Google Patents
ニコチンアミドモノヌクレオチドを含む化粧品組成物 Download PDFInfo
- Publication number
- WO2019078177A1 WO2019078177A1 PCT/JP2018/038392 JP2018038392W WO2019078177A1 WO 2019078177 A1 WO2019078177 A1 WO 2019078177A1 JP 2018038392 W JP2018038392 W JP 2018038392W WO 2019078177 A1 WO2019078177 A1 WO 2019078177A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- cosmetic composition
- composition according
- nicotinamide mononucleotide
- hair
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 title claims abstract 5
- 208000024891 symptom Diseases 0.000 claims abstract description 9
- 230000003779 hair growth Effects 0.000 claims description 15
- 230000009759 skin aging Effects 0.000 claims description 13
- 206010014970 Ephelides Diseases 0.000 claims description 9
- 208000003351 Melanosis Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 210000004761 scalp Anatomy 0.000 claims description 7
- 208000001840 Dandruff Diseases 0.000 claims description 6
- 208000003251 Pruritus Diseases 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 230000007803 itching Effects 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 23
- 206010040954 Skin wrinkling Diseases 0.000 abstract description 9
- 230000032683 aging Effects 0.000 abstract description 9
- 230000037303 wrinkles Effects 0.000 abstract description 6
- 238000007665 sagging Methods 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 67
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 53
- 239000000047 product Substances 0.000 description 27
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 20
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 16
- 229950006238 nadide Drugs 0.000 description 15
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 15
- 229960003966 nicotinamide Drugs 0.000 description 13
- 235000005152 nicotinamide Nutrition 0.000 description 13
- 239000011570 nicotinamide Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 11
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- -1 fatty acid esters Chemical class 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 230000037353 metabolic pathway Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000002087 whitening effect Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000001968 nicotinic acid Nutrition 0.000 description 6
- 229960003512 nicotinic acid Drugs 0.000 description 6
- 239000011664 nicotinic acid Substances 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000000344 soap Substances 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000008341 cosmetic lotion Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 4
- JOUIQRNQJGXQDC-ZYUZMQFOSA-L nicotinate D-ribonucleotide(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1[N+]1=CC=CC(C([O-])=O)=C1 JOUIQRNQJGXQDC-ZYUZMQFOSA-L 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 230000036558 skin tension Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 229940043375 1,5-pentanediol Drugs 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000011990 Sirtuin Human genes 0.000 description 3
- 108050002485 Sirtuin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000010445 mica Substances 0.000 description 3
- 229910052618 mica group Inorganic materials 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229940093932 potassium hydroxide Drugs 0.000 description 3
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 230000036620 skin dryness Effects 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 2
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- SENPVEZBRZQVST-HISDBWNOSA-N deamido-NAD zwitterion Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 SENPVEZBRZQVST-HISDBWNOSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 229940100524 ethylhexylglycerin Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 235000020956 nicotinamide riboside Nutrition 0.000 description 2
- 239000011618 nicotinamide riboside Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229910052628 phlogopite Inorganic materials 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000003658 preventing hair loss Effects 0.000 description 2
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- MVOSYKNQRRHGKX-UHFFFAOYSA-N 11-Undecanolactone Chemical compound O=C1CCCCCCCCCCO1 MVOSYKNQRRHGKX-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ZSNLEVJATWJBLU-UHFFFAOYSA-N 2-tert-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(C(C)(C)C)(OC)C(=O)C1=CC=CC=C1 ZSNLEVJATWJBLU-UHFFFAOYSA-N 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 229940122097 Collagenase inhibitor Drugs 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 240000002871 Tectona grandis Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010044625 Trichorrhexis Diseases 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZYPMNZKYVVSXOJ-FRRDWIJNSA-N [(2s,3s,4s)-2,3,4-triacetyloxy-5-oxopentyl] acetate Chemical compound CC(=O)OC[C@H](OC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)C=O ZYPMNZKYVVSXOJ-FRRDWIJNSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-MROZADKFSA-N aldehydo-L-ribose Chemical compound OC[C@H](O)[C@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-MROZADKFSA-N 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- SXQXMCWCWVCFPC-UHFFFAOYSA-N aluminum;potassium;dioxido(oxo)silane Chemical compound [Al+3].[K+].[O-][Si]([O-])=O.[O-][Si]([O-])=O SXQXMCWCWVCFPC-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940078469 dl- cysteine Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- TUHMQDODLHWPCC-UHFFFAOYSA-N formyl cyanide Chemical compound O=CC#N TUHMQDODLHWPCC-UHFFFAOYSA-N 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940072880 peg-10 stearate Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000011252 protective cream Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- XUXNAKZDHHEHPC-UHFFFAOYSA-M sodium bromate Chemical compound [Na+].[O-]Br(=O)=O XUXNAKZDHHEHPC-UHFFFAOYSA-M 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000010956 sodium stearoyl-2-lactylate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- KNYAZNABVSEZDS-UHFFFAOYSA-M sodium;2-octadecanoyloxypropanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C([O-])=O KNYAZNABVSEZDS-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000001040 synthetic pigment Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- XMLSXPIVAXONDL-UHFFFAOYSA-N trans-jasmone Natural products CCC=CCC1=C(C)CCC1=O XMLSXPIVAXONDL-UHFFFAOYSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- ISDBYDBAKGWSCA-UHFFFAOYSA-N trimethoxy phosphate Chemical compound COOP(=O)(OOC)OOC ISDBYDBAKGWSCA-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000012463 white pigment Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- ZNVKGUVDRSSWHV-UHFFFAOYSA-L zinc;4-hydroxybenzenesulfonate Chemical compound [Zn+2].OC1=CC=C(S([O-])(=O)=O)C=C1.OC1=CC=C(S([O-])(=O)=O)C=C1 ZNVKGUVDRSSWHV-UHFFFAOYSA-L 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/002—Preparations for repairing the hair, e.g. hair cure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- the present invention relates to a cosmetic composition having a moisturizing effect to impart lasting moisture to the skin, and an effect to prevent or ameliorate aging conditions such as wrinkles and sags, and more particularly to a cosmetic composition containing nicotinamide mononucleotide. .
- the moisture of the skin is maintained by the moisture in the stratum corneum and the sebum film on the surface of the skin, when the air dries, the moisture in the skin is lost and it tends to dry.
- blood circulation worsens due to cold, and sebum on the surface of the skin decreases, so that the water in the skin is likely to evaporate and drying of the skin further progresses.
- the moisturizing ingredient gradually decreases in production with age, and the skin becomes thirsty even with aging. Therefore, in recent years, people's awareness of skin care for preventing skin dryness and keeping moisture has been greatly increased.
- Such cosmetics are generally provided in the form of lotions, emulsions or creams. Lotions are used to make up the skin for moisture and moisturizing ingredients, and emulsions and creams are usually used after makeup water to replenish the skin with moisture and moisturizing ingredients and make a sebum film on the surface of the skin. It plays a role of protecting the surface.
- moisturizing ingredients to prevent skin dryness and keep the skin moist
- moisturizing ingredients included in general cosmetics include hyaluronic acid, collagen, elastin, ceramide, Hydrogenated soybean lecithin, polyethylene glycol, heparin analogues, proteoglycans and the like are well known.
- soybean seeds, soybean germs, soybean embryos having moisturizing action, collagen formation promoting action, hyaluronic acid production promoting action, cell activating action, antioxidant action, anti-aging action, hair growth action and rough skin improving action examples include soybean seeds, soybean germs, soybean embryos having moisturizing action, collagen formation promoting action, hyaluronic acid production promoting action, cell activating action, antioxidant action, anti-aging action, hair growth action and rough skin improving action.
- a plant-derived polyamine-containing extract derived from at least one material selected from the group consisting of soybean sprouts, wheat seeds, wheat germs, wheat germs, wheat germs, soybean milk and okara, and a whitening agent Cosmetic compositions have been reported (Patent Document 2).
- a cosmetic composition comprising a combination of at least two osmolytes selected from the group comprising taurine or a derivative thereof, inositol, betaine and trehalose as a composition to weaken or promote long life of cells or tissues It is reported (patent document 3).
- the moisturizing ingredients used in conventional cosmetics have high moisturizing agents to improve their functions.
- the concentration is blended, the sticky feeling becomes stronger, or the moisturizing component itself retains moisture to give moisture, so it lacks the sustainability of the moisturizing effect, so it is necessary to be frequently applied to the skin, and the moisturizing property is essential Problems such as not improving the
- the functional cosmetic which is a cosmetic product having a therapeutic aspect to ordinary skin care by blending the component used for medicine, in addition to the whitening effect, sun protection effect, etc.
- the effect anti-aging effect
- development of a cosmetic having these effects is also awaited.
- An object of the present invention is to provide a cosmetic composition having a moisturizing effect for imparting sustained moisture to the skin, and an effect for preventing or improving aging symptoms such as wrinkles and sags.
- nicotinamide mononucleotide which is an intermediate metabolite involved in biosynthesis of coenzyme NAD (nicotinamide adenine dinucleotide). It has been found that a moisturizing effect and the like can be obtained, and the present invention has been completed.
- the present invention is as follows.
- [1] A cosmetic composition comprising nicotinamide mononucleotide.
- the cosmetic composition according to the present invention imparts lasting moisturizing to the skin to improve moisturizing properties, and further has effects such as preventing or ameliorating aging symptoms such as wrinkles and sags.
- the cosmetic composition according to the present invention is characterized by containing nicotinamide mononucleotide, and by blending this, a sustained moisturizing effect and the like can be obtained.
- the “sertuin” represented by the NAD + -dependent deacetylase Sirt 1 and Sirt 3 is a nicotinamide
- nicotinamide mononucleotide when applied to the keratin of the skin, it is absorbed to increase the amount of nicotinamide mononucleotide in cells of the skin, and it is metabolized to increase the amount of NAD to activate sirtuin. Ru. Then, the sirtuin in the epidermis is activated to promote the production of natural moisturizing factors, and as a result, it is possible to obtain skin moisturizing effects and aging preventing and improving effects.
- the present invention will be described in detail.
- Nicotinamide mononucleotide (chemical formula: C 11 H 15 N 2 O 8 P) contained in the cosmetic composition according to the present invention is a compound represented by the following structural formula [Chemical Formula 1], and generally, NMN (Nicotinamide mononucleotide) ) And is known as an intermediate metabolite involved in the biosynthesis of coenzyme NAD + .
- NAD nicotinamide adenine dinucleotide
- Figure 1 is an explanatory view showing the metabolic pathways involved in niacin (generic name of nicotinamide and nicotinic acid) known as vitamin B 3. Nicotine acid ingested from the diet is taken up by the liver and converted to nicotinamide, which is delivered systemically via the bloodstream. Each cell takes in nicotinamide from blood, converts it to NAD and NADP, and uses it. Nicotinamide is also biosynthesized from tryptophan.
- tryptophan when tryptophan is used as a starting material in vivo, tryptophan is converted to quinolinic acid (QA) via the kynurenine pathway which is a tryptophan metabolic pathway, and is further converted to nicotinic acid mononucleotide (NaMN). (De novo route).
- QA quinolinic acid
- NaMN nicotinic acid mononucleotide
- NaMN nicotinic acid
- NaMN nicotinic acid
- NaMN is then interconverted with NAD, nicotinamide (NaM), nicotinamide mononucleotide by the NAD cycle via nicotinic acid adenine dinucleotide (NaAD).
- Nicotinamide (NaM) is converted to nicotinamide mononucleotide by nicotinamide phosphoribosyltransferase (NAMPT), and then nicotinamide mononucleotide is converted by nicotinamide mononucleotide adenyltransferase (NMNAT) to produce NAD (Salvage) Route).
- nicotinamide mononucleotide is also produced from nicotinamide riboside (NR) which is an NAD intermediate metabolite.
- Nicotinamide mononucleotide for example, synthesizes nicotinamide riboside from nicotinamide and ribose (see Bioorg. Med. Chem. Lett., 12, 1135-1137 (2002)), and then, for the 5-hydroxyl group of the ribose moiety. It can be obtained by phosphorylation (see Chem. Comm., 1999, 729-730).
- nicotinamide and L-ribose tetraacetate are dissolved in anhydrous acetonitrile, and an excess of trimethylsilyl trifluorosulfonic acid is added under a nitrogen stream, and then stirred at room temperature, and methanol is added.
- the reaction solution which has been quenched is applied to a column packed with activated carbon, washed with distilled water, and eluted with methanol to recover the product.
- nicotinamide mononucleotides are commercially available, and those commercially available products can be purchased and used.
- the compounding amount of nicotinamide mononucleotide may be appropriately determined according to the purpose of use, frequency of use, age, condition, body weight, age etc.
- the content is preferably 0.0001 to 40% by mass, more preferably 0.0001 to 20% by mass, and still more preferably 0.001 to 10% by mass. If the amount is less than 0.0001% by mass, the effects of the present invention may not be obtained. If the amount is more than 40% by mass, the cost is disadvantageous.
- the nicotinamide mononucleotide compounded in the cosmetic composition according to the present invention is a purified product having a low content of impurities, in particular, its purity is preferably 90% or more, more preferably 95% or more. If the purity is less than 90%, an offensive odor may be generated, or the action of nicotinamide mononucleotide may be attenuated and the effects of the present invention may not be sufficiently obtained.
- the impurities include, as shown in FIG.
- metabolites other than nicotinamide mononucleotide involved in the NAD metabolic pathway particularly nicotinamide and nicotinamide adenine dinucleotide.
- the presence of contaminants such as the above-mentioned metabolites involved in the NAD metabolic pathway in the nicotinamide mononucleotide used in the present invention reduces the uptake of nicotinamide mononucleotide into living cells, etc. As a result, the effects of the present invention may be diminished.
- a test solution of dried nicotinamide mononucleotide powder is injected into an HPLC apparatus, the peak area of the obtained chromatograph is determined, and absolute calibration using a standard sample is performed.
- the line method is performed (vertical axis: peak area, horizontal axis: concentration).
- a trace amount of substance since it can be quantified accurately by using the peak height, it is appropriately selected according to the characteristics of the apparatus to be used.
- identification of the separated substance is performed by retention time.
- the cosmetic composition according to the present invention can be applied to the face, hands, etc. to moisturize their skin and be used to continuously improve the moisture retention of the skin. Persistence of the moisturizing effect is one of the features of the present invention.
- the application of the present invention increases the amount of water in the skin and improves the moisture retention of the skin, thereby improving the dryness, firmness, elasticity, flexibility, and the like of the skin.
- nicotinamide mononucleotide affects the natural moisturizing factor and the promotion of intercorneocyte lipid production, promotes the formation of hyaluronic acid, and the like as the reason why the present invention improves the skin's moisturizing property.
- nicotinamide mononucleotide can itself be used as a moisturizer, and can also be used to produce a moisturizer.
- the cosmetic composition according to the present invention can be applied to the face, hands and the like to be used for preventing and ameliorating the skin's aging symptoms.
- the "skin aging condition” mainly refers to the generation of wrinkles and sags, loss of skin tension and the like due to the decrease in elasticity of the skin with age.
- the reason why the present invention can prevent or ameliorate the skin's aging condition is considered to be that the nicotinamide mononucleotide stimulates the deteriorated skin metabolic function, promotes collagen formation, and the like.
- nicotinamide mononucleotide can be used by itself as an agent for preventing or ameliorating skin aging, and can also be used to produce an agent for preventing or ameliorating skin aging.
- the cosmetic composition according to the present invention can be applied to the scalp and hair to be used to obtain hair growth and hair growth effects.
- nicotinamide mononucleotide activates hair matrix cells.
- nicotinamide mononucleotide can be used by itself as a hair growth agent, a hair growth agent, or can be used to produce a hair growth agent, a hair growth agent.
- the cosmetic composition according to the present invention can be used to prevent the formation and deposition of melanin caused by sunburn and the like, and to obtain a whitening effect that prevents or improves skin spots and freckles.
- a whitening effect that prevents or improves skin spots and freckles.
- nicotinamide mononucleotide promotes the excretion of melanin.
- nicotinamide mononucleotide can be used as a whitening agent by itself and can be used to produce a whitening agent.
- the cosmetic composition according to the present invention can be used to prevent or ameliorate the skin roughening that occurs under the influence of the external environment or the influence of the internal environment. It is more effective to appropriately blend an anti-inflammatory agent, a vitamin, a hormone, a plant extract, a bactericidal agent, an oil component and the like according to the cause of the rough skin.
- the reason why the present invention provides a preventive and ameliorating effect on rough skin is considered that nicotinamide mononucleotide improves the function of sirtuin in skin tissue.
- nicotinamide mononucleotide can be used by itself as an agent for preventing or ameliorating skin roughness, and can be used to produce an agent for preventing or ameliorating skin roughness.
- the cosmetic composition according to the present invention can be used to reduce dandruff and itching of the scalp.
- the reason why the present invention provides a suppressive effect on dandruff and itch of the scalp is considered that nicotinamide mononucleotide acts on the scalp to suppress inflammation of the scalp.
- the cosmetic composition according to the present invention can be used to prevent tears, cuts and splits.
- the reason why the present invention can provide the effect of preventing hair loss, hair breakage and split hair is considered that nicotinamide mononucleotide acts on the hair to reinforce the cuticle and promote its production.
- the cosmetic composition according to the present invention can be used as a cosmetic or quasi drug.
- cosmetics refers to rubbing, spreading or the like on the body in order to cleanse, beautify, increase the attraction, change the appearance of the human body, or keep the skin or hair healthy. It is intended to be used, and is defined as a substance that acts on the human body.
- quasi-drug is a substance used for the purpose of preventing nausea or other discomfort, bad breath or body odor, preventing heat buildup, sore, etc., preventing hair loss, hair growth or hair removal, And, it refers to something that has a modest effect on the human body.
- the cosmetics or quasi-drugs according to the present invention it is preferably used on the skin about once to about 5 times a day for several days to several months until the desired effect is obtained.
- the dose of the cosmetic or quasi-drug according to the present invention depends on the content of nicotinamide mononucleotide, the desired effect, the form of the cosmetic or quasi-drug, the condition of the target person, body weight, age, etc. It may be determined appropriately.
- the cosmetic composition according to the present invention can be provided in various forms. Specifically, face wash (soap soap, cosmetic soap, face wash foam, face wash cream, etc.), makeup remover (cleansing cream etc.), cleansing cosmetics, lotion, essence, pack for skin care, protection Skin care cosmetics such as milky lotion (moisture lotion), protective cream (moisture cream), protective cosmetics, whitening cosmetics, UV protection cosmetics etc. foundation, white powder (face powder), makeup base, base makeup cosmetics, lipstick, eye makeup ( Eye shadow, eyeliner etc.), blusher (teak color), nail enamel (nail enamel remover etc.), point makeup cosmetic etc.
- face wash soap, cosmetic soap, face wash foam, face wash cream, etc.
- makeup remover cleaning cream etc.
- cleansing cosmetics lotion, essence, pack for skin care
- protection Skin care cosmetics such as milky lotion (moisture lotion), protective cream (moisture cream), protective cosmetics, whitening cosmetics, UV protection cosmetics etc. foundation, white powder (face powder), makeup base, base makeup
- make-up cosmetics shampoo, hair rinse, hair treatment, hair conditioner, hair wash cosmetics, hair styling cosmetics , Hair Hair care cosmetics such as hair mousse, hair spray, hair styling gel, hair wax, hair oil, pomade, tic, hair liquid, hair setting agent, permanent wave agent, hair dye, decolorizing agent, decolorizing agent, hair restorer and the like; Bath soap, body shampoo, hand soap, body washing cosmetics, deodorant cosmetics, body care cosmetics such as bath preparations; toothpaste; perfume cosmetics such as perfume, eau de cologne, eau de toilette, etc.
- the cosmetic composition according to the present invention may be a base material constituting the base of the cosmetic composition, a quality-retaining material necessary for maintaining the quality, or a sensory material for imparting color or smell according to the purpose of use, etc.
- the feature imparting raw material and the like are appropriately blended.
- oil components such as hydrocarbons, vegetable oils, animal oils, higher alcohols, fatty acids, fatty acid esters, silicone oils, polyhydric alcohols, polyhydric alcohol ethers, alkyl glyceryl ethers, fluorine oils, etc .; anionics, positives Ionic, zwitterionic, and nonionic surfactants; polyhydric alcohols, saccharides, water-soluble biopolymers (hyaluronic acid, collagen, elastin, albumin, casein sodium, pyrrolidone carboxylic acid, etc.), natural moisturizing factors (PCA-Na etc.), amino acids, moisturizing components such as urea, water soluble polymers (carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carrageenan, guar gum, xanthan gum, cellulose gum, poval, PVP, cationized cellulose etc.), Biopolymer ( Sodium arronate, collagen, albumin etc.
- Benzyl benzoate methyl benzoate, vanillin, ethyl vanillin, undecalactone, coumarin, caffeine aldehyde, caffeine alcohol, ethyl cinnamic acid, geraniol, citronellal, salicylic acid ester, benzyl alcohol, methylacetophenone, synthetic perfume such as phenethyl alcohol; Ethyl PABA, oxybenzone-1 UV absorbers such as oxybenzone-6, homosalate, t-butylmethoxydibenzoylmethane and oryzanol; UV scattering agents such as titanium oxide and zinc flower; benzoic acid, salicylic acid, ethyl paraben, butyl paraben, sorbic acid, phenoxyethanol, dehydro Antiseptics such as sodium acetate and p-hydroxybenzoic acid ester; benzalkonium chloride, benzethonium chloride, quaternary ammonium salt,
- ethanolamine, DEA, TEA sodium hydroxide, citric acid, tartaric acid, sodium acetate PH modifiers such as glycolic acid and lactic acid; oxidizing agents such as hydrogen peroxide and sodium bromate; reducing agents such as mercaptoacetic acid, DL-cysteine and sodium sulfite; penetrating agents such as benzyl alcohol; ethyl acetate and butyl acetate And solvents such as ethanol and water.
- oxidizing agents such as hydrogen peroxide and sodium bromate
- reducing agents such as mercaptoacetic acid, DL-cysteine and sodium sulfite
- penetrating agents such as benzyl alcohol; ethyl acetate and butyl acetate
- solvents such as ethanol and water.
- the cosmetic composition according to the present invention may be blended a component having a mild pharmacological action to be blended in ordinary cosmetics, cosmeceutical products, quasi-drugs and the like, as long as the effects of the present invention are not impaired. it can.
- skin lightening agents such as vitamin C and derivatives thereof; blood circulation promoting agents such as tocopherol, pepper extract, cerebrum extract, garlic extract, ginseng extract, etc .; hair matrix cell activator, anti-androgen Agents, anti-inflammatory agents, anti-dandruff agents, hair-growth agents such as antipruritic agents; anti-inflammatory agents, vitamins, hormones, plant extracts and other rough skin inhibitors; antioxidants (vitamin C, tocopherol, carotene, epicatechin, glycyrrhetin) Acid, etc., cell activator, collagenase inhibitor, elastase inhibitor, etc .; sebum secretion inhibitor, stratum corneum release / dissolving agent, bactericidal agent, anti-inflammatory agent (alantoin, aminocaproic acid, calcium pantothenate, pro vitamin B 5, glycyrrhetinic acid, acne agent lysozyme chloride, etc.) and the like
- the cosmetic composition according to the present invention is appropriately selected from nicotinamide mononucleotide and the other components described above according to the purpose of use, form, etc. It may be manufactured by the method of
- nicotinamide mononucleotide By a conventional method, nicotinamide mononucleotide, glyceryl stearate, PEG-10 stearate, sorbitan stearate, horse oil, dimethicone, behenyl alcohol, cetearyl glucoside, jojoba seed oil, olive fruit oil, EDTA-2Na, tocopherol, pentastearin Acid polyglyceryl-10, ethylhexylglycerin, sodium stearoyl lactate, potassium hydroxide, water, rice bran oil, tri (caprylic acid / capric acid), glyceryl, glycerin, pentylene glycol, dipropylene glycol, sedeallyl alcohol, glyceryl stearate Uniformly mixed, and containing 0.1% by mass of nicotinamide mononucleotide (Invention product 3, "FACE RICH SKIN CREAM", trade name,
- Example 1 The cosmetic lotion (inventive product 1) produced in Production Example 1 was continuously used for 27 months for 27 subjects (8 males, 19 females, 28 to 70 years old) for 2 months and started using it Two weeks after, one month after, and two months after, self-assessment of the skin's moisturizing properties (skin dryness, firmness, elasticity, flexibility) according to the criteria shown in Table 1
- the Table 1 shows the results of the number of evaluated persons for each criterion.
- Example 2 The cosmetic lotion (inventive product 1) produced in Production Example 1 was continuously used for 27 months for 27 subjects (8 males, 19 females, 28 to 70 years old) for 2 months and started using it Two weeks after, one month after, and two months after, the self-assessment was performed based on the criteria shown in Table 1 for skin aging symptoms (wrinkling, sagging, loss of skin tension) The Table 1 shows the results of the number of evaluated persons for each criterion.
- Example 3 The cosmetic lotion (inventive product 1) produced in Production Example 1 was continuously used for 27 months for 27 subjects (8 males, 19 females, 28 to 70 years old) for 2 months and started using it Two weeks after, one month after, and two months after, the skin spots and freckles were evaluated on the basis of the criteria shown in Table 1. Table 1 shows the results of the number of evaluated persons for each criterion.
- Example 4 The cosmetic lotion (inventive product 1) produced in Production Example 1 was continuously used for 27 months for 27 subjects (8 males, 19 females, 28 to 70 years old) for 2 months and started using it Two weeks after, one month after, and two months after, the self-evaluation was carried out based on the criteria shown in Table 1 for rough skin. Table 1 shows the results of the number of evaluated persons for each criterion.
- Example 5 The cosmetic solution (inventive product 2) produced in Production Example 2 was continuously used for 30 months by 30 subjects (11 males, 19 females, 33 to 79 years old) for 2 months and started using it Two weeks after, one month after, and two months after, self-assessment of skin moisturizing property (dryness, firmness, elasticity, flexibility of skin) according to the criteria shown in Table 2
- Table 2 shows the results of the number of persons evaluated for each criterion.
- Example 6 The cosmetic solution (inventive product 2) produced in Production Example 2 was continuously used for 30 months by 30 subjects (11 males, 19 females, 33 to 79 years old) for 2 months and started using it Two weeks after, one month after, and two months after, the self-assessment was performed based on the criteria shown in Table 2 for skin aging symptoms (wrinkling, sagging, loss of skin tension) The Table 2 shows the results of the number of persons evaluated for each criterion.
- Example 7 The cosmetic solution (inventive product 2) produced in Production Example 2 was continuously used for 30 months by 30 subjects (11 males, 19 females, 33 to 79 years old) for 2 months and started using it Two weeks after, one month after, and two months after, the skin spots and freckles were evaluated on the basis of the criteria shown in Table 2.
- Table 2 shows the results of the number of persons evaluated for each criterion.
- Example 8 The cosmetic solution (inventive product 2) produced in Production Example 2 was continuously used for 30 months by 30 subjects (11 males, 19 females, 33 to 79 years old) for 2 months and started using it Two weeks after, one month, and two months after, each subject was asked to self-assess the rough skin according to the criteria shown in Table 2.
- Table 2 shows the results of the number of persons evaluated for each criterion.
- Example 9 From 30 subjects (11 males, 19 females, 33-79 years old), the cream (inventive product 3) produced in Production Example 3 was continuously used for 2 months, and from the start of use Two weeks, one month, and two months later, they were asked to evaluate their skin's moisturizing properties (dryness, firmness, elasticity, flexibility of the skin) according to the criteria shown in Table 3. .
- Table 3 shows the results of the number of persons evaluated for each criterion.
- Example 10 From 30 subjects (11 males, 19 females, 33-79 years old), the cream (inventive product 3) produced in Production Example 3 was continuously used for 2 months, and from the start of use Self-assessment was performed on the criteria shown in Table 3 for skin aging symptoms (wrinkling, sagging, loss of skin tension) after 2 weeks, 1 month, and 2 months. . Table 3 shows the results of the number of persons evaluated for each criterion.
- Example 11 The cosmetic solution (inventive product 3) produced in Production Example 3 was continuously used for 30 months by 30 subjects (11 males, 19 females, 33 to 79 years old) for two months and started using it Two weeks after, one month after, and two months after, the skin spots and freckles were evaluated on the basis of the criteria shown in Table 3.
- Table 3 shows the results of the number of persons evaluated for each criterion.
- Example 12 The cosmetic solution (inventive product 3) produced in Production Example 3 was continuously used for 30 months by 30 subjects (11 males, 19 females, 33 to 79 years old) for two months and started using it Two weeks after, one month, and two months after, each subject was asked to self-assess the rough skin according to the criteria shown in Table 3.
- Table 3 shows the results of the number of persons evaluated for each criterion.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
Description
[1]ニコチンアミドモノヌクレオチドを含む化粧品組成物。
[2]ニコチンアミドモノヌクレオチドの量が、全組成物の0.0001~40質量%である[1]の化粧品組成物。
[3]ニコチンアミドモノヌクレオチドの純度が90%以上である[1]又は[2]の化粧品組成物。
[4]皮膚の保湿性を向上させるために使用される[1]~[3]のいずれかの化粧品組成物。
[5]皮膚の老化症状を予防又は改善するために使用される[1]~[3]のいずれかの化粧品組成物。
[6]発毛又は育毛の促進のために使用される[1]~[3]のいずれかの化粧品組成物。
[7]皮膚のしみ、そばかすを予防又は改善するために使用される[1]~[3]のいずれかの化粧品組成物。
[8]肌荒れを予防又は改善するために使用される[1]~[3]のいずれかの化粧品組成物。
[9]頭皮のふけ、かゆみを抑えるために使用される[1]~[3]のいずれかの化粧品組成物。
[10]裂毛、切毛、枝毛を防ぐために使用される[1]~[3]のいずれかの化粧品組成物。
[11]化粧品又は医薬部外品として使用される[1]~[10]のいずれかの化粧品組成物。
常法により、ニコチンアミドモノヌクレオチド、ヒアルロン酸ナトリウム、PEG-20ソルビタンココエート、エチルヘキシルグリセリン、水酸化カリウム、水、ブチレングリコール、グリセリン、及びペンチレングリコールを均一に混合し、ニコチンアミドモノヌクレオチドを0.1質量%含む化粧水(本発明品1、「FACE RICH」、商品名、新興和製薬社製)を製造した。
常法により、ニコチンアミドモノヌクレオチド、ヒアルロン酸ナトリウム、キサンタンガム、エチルヘキシルグリセリン、水酸化カリウム、水、ブチレングリコール、グリセリン、及びペンチレングリコールを均一に混合し、ニコチンアミドモノヌクレオチドを1.0%含む美容液(本発明品2、「FACE RICH SKIN ESSENCE」、商品名、新興和製薬社製)を製造した。
常法により、ニコチンアミドモノヌクレオチド、ステアリン酸グリセリル、ステアリン酸PEG-10、ステアリン酸ソルビタン、馬油、ジメチコン、ベヘニルアルコール、セテアリルグルコシド、ホホバ種子油、オリーブ果実油、EDTA-2Na、トコフェロール、ペンタステアリン酸ポリグリセリル-10、エチルヘキシルグリセリン、ステアロイル乳酸ナトリウム、水酸化カリウム、水、コメヌカ油、トリ(カプリル酸/カプリン酸)、グリセリル、グリセリン、ペンチレングリコール、ジプロピレングリコール、セデアリルアルコール、ステアリン酸グリセリルを均一に混合し、ニコチンアミドモノヌクレオチドを0.1質量%含むクリーム(本発明品3、「FACE RICH SKIN CREAM」、商品名、新興和製薬社製)を製造した。
製造例1で製造した化粧水(本発明品1)を、被験者27名(男性8名、女性19名、28~70歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、皮膚の保湿性(肌の乾燥、張り、弾力性、柔軟性)について表1に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表1に示す。
製造例1で製造した化粧水(本発明品1)を、被験者27名(男性8名、女性19名、28~70歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、皮膚の老化症状(しわ、たるみの発生、皮膚の張りの喪失)について表1に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表1に示す。
製造例1で製造した化粧水(本発明品1)を、被験者27名(男性8名、女性19名、28~70歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、皮膚のしみ、そばかすについて表1に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表1に示す。
製造例1で製造した化粧水(本発明品1)を、被験者27名(男性8名、女性19名、28~70歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、肌荒れについて表1に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表1に示す。
表1に示した結果から分かるように、本発明品1が、皮膚の保湿性、皮膚の老化症状、皮膚のしみ、そばかす、肌荒れの改善に有効であることが確認された。
製造例2で製造した美容液(本発明品2)を、被験者30名(男性11名、女性19名、33~79歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、皮膚の保湿性(肌の乾燥、張り、弾力性、柔軟性)について表2に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表2に示す。
製造例2で製造した美容液(本発明品2)を、被験者30名(男性11名、女性19名、33~79歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、皮膚の老化症状(しわ、たるみの発生、皮膚の張りの喪失)について表2に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表2に示す。
製造例2で製造した美容液(本発明品2)を、被験者30名(男性11名、女性19名、33~79歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、皮膚のしみ、そばかすについて表2に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表2に示す。
製造例2で製造した美容液(本発明品2)を、被験者30名(男性11名、女性19名、33~79歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、肌荒れについて表2に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表2に示す。
表2に示した結果から分かるように、本発明品2が、皮膚の保湿性、皮膚の老化症状、皮膚のしみ、そばかす、肌荒れの改善に有効であることが確認された。
製造例3で製造したクリーム(本発明品3)を、被験者30名(男性11名、女性19名、33~79歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、皮膚の保湿性(肌の乾燥、張り、弾力性、柔軟性)について表3に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表3に示す。
製造例3で製造したクリーム(本発明品3)を、被験者30名(男性11名、女性19名、33~79歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、皮膚の老化症状(しわ、たるみの発生、皮膚の張りの喪失)について表3に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表3に示す。
製造例3で製造した美容液(本発明品3)を、被験者30名(男性11名、女性19名、33~79歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、皮膚のしみ、そばかすについて表3に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表3に示す。
製造例3で製造した美容液(本発明品3)を、被験者30名(男性11名、女性19名、33~79歳)に対して、2か月間継続して使用してもらい、使用開始から2週間後、1か月後、及び2か月後のそれぞれにおいて、肌荒れについて表3に示す基準にて自己評価をしてもらった。各基準に対する評価人数の結果を表3に示す。
表3に示した結果から分かるように、本発明品3が、皮膚の保湿性、皮膚の老化症状、皮膚のしみ、そばかす、肌荒れの改善に有効であることが確認された。
Claims (11)
- ニコチンアミドモノヌクレオチドを含むことを特徴とする化粧品組成物。
- ニコチンアミドモノヌクレオチドの量が、全組成物の0.0001~40質量%である請求項1に記載の化粧品組成物。
- ニコチンアミドモノヌクレオチドの純度が90%以上である請求項1又は2に記載の化粧品組成物。
- 皮膚の保湿性を向上させるために使用される請求項1~3のいずれか1項に記載の化粧品組成物。
- 皮膚の老化症状を予防又は改善するために使用される請求項1~3のいずれか1項に記載の化粧品組成物。
- 発毛又は育毛の促進のために使用される請求項1~3のいずれか1項に記載の化粧品組成物。
- 皮膚のしみ、そばかすを予防又は改善するために使用される請求項1~3のいずれか1項に記載の化粧品組成物。
- 肌荒れを予防又は改善するために使用される請求項1~3のいずれか1項に記載の化粧品組成物。
- 頭皮のふけ、かゆみを抑えるために使用される請求項1~3のいずれか1項に記載の化粧品組成物。
- 裂毛、切毛、枝毛を防ぐために使用される請求項1~3のいずれか1項に記載の化粧品組成物。
- 化粧品又は医薬部外品として使用される請求項1~10のいずれか1項に記載の化粧品組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880067285.7A CN111225657A (zh) | 2017-10-16 | 2018-10-16 | 一种含有烟酰胺单核苷酸的化妆品组合物 |
EP18868820.4A EP3698771A4 (en) | 2017-10-16 | 2018-10-16 | COSMETIC COMPOSITION CONTAINING NICOTINAMIDE MONONUCLEOTIDE |
JP2019549280A JPWO2019078177A1 (ja) | 2017-10-16 | 2018-10-16 | ニコチンアミドモノヌクレオチドを含む化粧品組成物 |
US16/755,692 US20210196612A1 (en) | 2017-10-16 | 2018-10-16 | Cosmetic composition containing nicotinamide mononucleotide |
KR1020207014236A KR20200074176A (ko) | 2017-10-16 | 2018-10-16 | 니코틴아미드모노뉴클레오티드를 포함하는 화장품 조성물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-199979 | 2017-10-16 | ||
JP2017199979 | 2017-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019078177A1 true WO2019078177A1 (ja) | 2019-04-25 |
Family
ID=66174036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/038392 WO2019078177A1 (ja) | 2017-10-16 | 2018-10-16 | ニコチンアミドモノヌクレオチドを含む化粧品組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210196612A1 (ja) |
EP (1) | EP3698771A4 (ja) |
JP (1) | JPWO2019078177A1 (ja) |
KR (1) | KR20200074176A (ja) |
CN (1) | CN111225657A (ja) |
WO (1) | WO2019078177A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111184732A (zh) * | 2020-03-04 | 2020-05-22 | 武汉华纳联合药业有限公司 | 一种复合组合物制剂及其制备方法和皮肤炎症中的应用 |
CN112823778A (zh) * | 2019-11-21 | 2021-05-21 | 百瑞全球有限公司 | 毛发护理组合物及其制备方法 |
WO2021144843A1 (ja) * | 2020-01-14 | 2021-07-22 | 株式会社ハーバーリンクスジャパン | バイオ化粧品組成物 |
CN113768861A (zh) * | 2021-10-09 | 2021-12-10 | 热休(厦门)细胞生物科技有限公司 | 一种具有防脱育发功能的外泌体美容液及其制备方法 |
JP2022024400A (ja) * | 2020-07-28 | 2022-02-09 | エリジオンサイエンス株式会社 | 発育毛剤 |
WO2023282283A1 (ja) * | 2021-07-07 | 2023-01-12 | 明治ホールディングス株式会社 | 口腔環境改善用組成物 |
WO2023106376A1 (ja) * | 2021-12-09 | 2023-06-15 | 国立大学法人九州大学 | コラーゲン産生促進剤、ヒアルロン酸産生促進剤、及び表皮角化細胞賦活剤 |
WO2023175655A1 (ja) * | 2022-03-14 | 2023-09-21 | ミライラボバイオサイエンス株式会社 | 口腔疾患用剤 |
JP7610823B1 (ja) * | 2024-08-26 | 2025-01-09 | 株式会社ゆうき | 細胞賦活剤 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109908067A (zh) * | 2019-04-11 | 2019-06-21 | 聂乐明 | 用于生发和防止脱发的组合物及其制备方法和应用 |
TWI834988B (zh) * | 2020-08-25 | 2024-03-11 | 大江生醫股份有限公司 | 富含菸醯胺單核苷酸的酵母粉的製備方法、酵母粉及其改善肌膚狀況、頭髮護理、抗發炎、心血管保健、抗氧化、抗老化及/或改善身體疲憊程度之用途 |
CN112618400A (zh) * | 2021-01-29 | 2021-04-09 | 山东华熙海御生物医药有限公司 | 一种改善肤色的组合物及美白化妆品 |
CN112791008B (zh) * | 2021-01-29 | 2022-06-21 | 中粮集团有限公司 | 辅酶在抗衰老美容护肤品中的应用及含辅酶的护肤品及其制备方法 |
CN119013038A (zh) * | 2022-04-08 | 2024-11-22 | 创新外科再生控股有限公司 | 用于伤口愈合和促进毛发生长和/或再生的nampt |
CN114748379B (zh) * | 2022-05-05 | 2023-10-24 | 有货(北京)信息技术有限公司 | 一种含有nmn的纯结晶型氨基酸洁面膏及其制备方法 |
CN115025000B (zh) * | 2022-05-19 | 2024-03-22 | 广州市金宸生物科技有限公司 | 一种具有抗皱、紧致功能的美白组合物及其应用 |
CN114748408A (zh) * | 2022-05-19 | 2022-07-15 | 有货(北京)信息技术有限公司 | 一种含有nmn的氨基酸沐浴露及其制备方法 |
CN115137661A (zh) * | 2022-07-07 | 2022-10-04 | 广州品域美妆创新科技有限公司 | 含β-烟酰胺单核苷酸的抗皱组合物及其制备方法、化妆品 |
CN115887348B (zh) * | 2022-12-29 | 2024-09-24 | 泉后(广州)生物科技研究院有限公司 | 一种修护头皮屏障的组合物及其制备方法和应用 |
PL443789A1 (pl) * | 2023-02-15 | 2024-08-19 | Be Bio Active Cosmetiqs Mind Network Inspire Spółka Z Ograniczoną Odpowiedzialnością Spółka Komandytowa | Kompozycja do pielęgnacji włosów |
PL443788A1 (pl) * | 2023-02-15 | 2024-08-19 | Be Bio Active Cosmetiqs Mind Network Inspire Spółka Z Ograniczoną Odpowiedzialnością Spółka Komandytowa | Kompozycja do pielęgnacji włosów |
CN116350538B (zh) * | 2023-04-17 | 2025-06-10 | 中山市天图精细化工有限公司 | 一种含β-烟酰胺单核苷酸的抗皱组合物气雾剂及其制备方法 |
CN116585230A (zh) * | 2023-06-09 | 2023-08-15 | 麦吉丽生物科技有限公司 | 具有皮肤紧致功效的组合物、发酵油及其制备方法和应用 |
CN117017813A (zh) * | 2023-08-16 | 2023-11-10 | 浙江睿颜新材料科技有限公司 | 一种减少皮肤皱纹的组合物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004217590A (ja) | 2003-01-16 | 2004-08-05 | Unitika Ltd | 化粧品組成物 |
JP2009234939A (ja) | 2008-03-26 | 2009-10-15 | Toyobo Co Ltd | 植物由来ポリアミン含有抽出物を含有する化粧品組成物 |
JP2010150258A (ja) | 2008-12-24 | 2010-07-08 | Lvmh Recherche | 保湿効果又は老化防止効果を有する少なくとも2つの浸透圧調節物質を含有する化粧品組成物 |
CN104771330A (zh) * | 2015-03-16 | 2015-07-15 | 邦泰生物工程(深圳)有限公司 | 一种含烟酰胺单核苷酸抗衰老美容护肤品组合物 |
JP2016135750A (ja) * | 2015-01-23 | 2016-07-28 | 株式会社ベスビオ | 化粧料 |
WO2017110317A1 (ja) * | 2015-12-21 | 2017-06-29 | 昭和電工株式会社 | ニコチンアミドモノヌクレオチド誘導体、その塩、その製造方法、皮膚外用剤、化粧料、食品添加剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160287621A1 (en) * | 2013-11-06 | 2016-10-06 | President And Fellows Of Harvard College | Biological production of nad precursors and analogs |
KR102325437B1 (ko) * | 2014-10-23 | 2021-11-10 | 주식회사 엘지생활건강 | 니코틴아미드 아데닌 디뉴클레오티드의 전구체를 포함하는 노화 방지용 화장료 조성물 |
CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
US20180177703A1 (en) * | 2015-06-25 | 2018-06-28 | N.V. Perricone Llc | Niacinamide Mononucleotide Formulations For Skin Aging |
WO2018147385A1 (ja) * | 2017-02-08 | 2018-08-16 | オリエンタル酵母工業株式会社 | 皮膚色素沈着抑制剤 |
JP7210459B2 (ja) * | 2017-09-14 | 2023-01-23 | めぐみ 田中 | 老化防止剤及び老化防止方法 |
-
2018
- 2018-10-16 JP JP2019549280A patent/JPWO2019078177A1/ja active Pending
- 2018-10-16 WO PCT/JP2018/038392 patent/WO2019078177A1/ja unknown
- 2018-10-16 US US16/755,692 patent/US20210196612A1/en not_active Abandoned
- 2018-10-16 EP EP18868820.4A patent/EP3698771A4/en not_active Withdrawn
- 2018-10-16 CN CN201880067285.7A patent/CN111225657A/zh active Pending
- 2018-10-16 KR KR1020207014236A patent/KR20200074176A/ko not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004217590A (ja) | 2003-01-16 | 2004-08-05 | Unitika Ltd | 化粧品組成物 |
JP2009234939A (ja) | 2008-03-26 | 2009-10-15 | Toyobo Co Ltd | 植物由来ポリアミン含有抽出物を含有する化粧品組成物 |
JP2010150258A (ja) | 2008-12-24 | 2010-07-08 | Lvmh Recherche | 保湿効果又は老化防止効果を有する少なくとも2つの浸透圧調節物質を含有する化粧品組成物 |
JP2016135750A (ja) * | 2015-01-23 | 2016-07-28 | 株式会社ベスビオ | 化粧料 |
CN104771330A (zh) * | 2015-03-16 | 2015-07-15 | 邦泰生物工程(深圳)有限公司 | 一种含烟酰胺单核苷酸抗衰老美容护肤品组合物 |
WO2017110317A1 (ja) * | 2015-12-21 | 2017-06-29 | 昭和電工株式会社 | ニコチンアミドモノヌクレオチド誘導体、その塩、その製造方法、皮膚外用剤、化粧料、食品添加剤 |
Non-Patent Citations (6)
Title |
---|
BIOORG. MED. CHEM. LETT., vol. 12, 2002, pages 1135 - 1137 |
CHEM. COMM., 1999, pages 729 - 730 |
DATABASE GNPD Mintel; December 2016 (2016-12-01), "Skin Cream", XP055596851, Database accession no. 4503719 * |
DATABASE GNPD Mintel; December 2016 (2016-12-01), "Skin Essence", XP055596850, Database accession no. 4503717 * |
DATABASE GNPD Mintel; December 2016 (2016-12-01), "Skin Water", XP055596848, Database accession no. 4503715 * |
See also references of EP3698771A4 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023517413A (ja) * | 2019-11-21 | 2023-04-26 | バイオライト・ワールドワイド・カンパニー・リミテッド | 毛髪ケア組成物及びその調製方法 |
CN112823778A (zh) * | 2019-11-21 | 2021-05-21 | 百瑞全球有限公司 | 毛发护理组合物及其制备方法 |
WO2021098874A1 (zh) * | 2019-11-21 | 2021-05-27 | 百瑞全球有限公司 | 毛发护理组合物及其制备方法 |
CN112823778B (zh) * | 2019-11-21 | 2024-06-14 | 百瑞全球有限公司 | 毛发护理组合物及其制备方法 |
EP4062897A4 (en) * | 2019-11-21 | 2024-04-17 | BioRight Worldwide Company Limited | HAIR CARE COMPOSITION AND METHOD FOR ITS PRODUCTION |
WO2021144843A1 (ja) * | 2020-01-14 | 2021-07-22 | 株式会社ハーバーリンクスジャパン | バイオ化粧品組成物 |
CN111184732B (zh) * | 2020-03-04 | 2023-09-08 | 武汉华纳联合药业有限公司 | 一种复合组合物制剂及其制备方法和皮肤炎症中的应用 |
CN111184732A (zh) * | 2020-03-04 | 2020-05-22 | 武汉华纳联合药业有限公司 | 一种复合组合物制剂及其制备方法和皮肤炎症中的应用 |
JP2022024400A (ja) * | 2020-07-28 | 2022-02-09 | エリジオンサイエンス株式会社 | 発育毛剤 |
WO2023282283A1 (ja) * | 2021-07-07 | 2023-01-12 | 明治ホールディングス株式会社 | 口腔環境改善用組成物 |
CN113768861A (zh) * | 2021-10-09 | 2021-12-10 | 热休(厦门)细胞生物科技有限公司 | 一种具有防脱育发功能的外泌体美容液及其制备方法 |
WO2023106376A1 (ja) * | 2021-12-09 | 2023-06-15 | 国立大学法人九州大学 | コラーゲン産生促進剤、ヒアルロン酸産生促進剤、及び表皮角化細胞賦活剤 |
WO2023175655A1 (ja) * | 2022-03-14 | 2023-09-21 | ミライラボバイオサイエンス株式会社 | 口腔疾患用剤 |
JP7610823B1 (ja) * | 2024-08-26 | 2025-01-09 | 株式会社ゆうき | 細胞賦活剤 |
Also Published As
Publication number | Publication date |
---|---|
EP3698771A1 (en) | 2020-08-26 |
EP3698771A4 (en) | 2021-08-25 |
US20210196612A1 (en) | 2021-07-01 |
JPWO2019078177A1 (ja) | 2020-11-05 |
KR20200074176A (ko) | 2020-06-24 |
CN111225657A (zh) | 2020-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019078177A1 (ja) | ニコチンアミドモノヌクレオチドを含む化粧品組成物 | |
JP4229842B2 (ja) | L−アルギニンオリゴマーを含む化粧品処方 | |
TWI652066B (zh) | 用於使皮膚回春之胜肽及其使用方法 | |
JP5572318B2 (ja) | 局所投与用アルギニンヘテロマー | |
JP2012041302A (ja) | 皮膚化粧料 | |
CN111000748A (zh) | 一种多肽修护面霜及其制备方法 | |
JP2886591B2 (ja) | 化粧料 | |
BR112014002595B1 (pt) | Uso de esfinganina para melhorar a aparência visual da pele e cabelo | |
JP2005187474A (ja) | 改善された香粧料 | |
TWI419709B (zh) | 外用組成物 | |
JP2017193506A (ja) | 皮膚化粧料 | |
JP2004091376A (ja) | 表皮角化正常化剤及びこれを含有する皮膚外用剤 | |
JP6356457B2 (ja) | セラミド配合外用剤組成物 | |
JP5455292B2 (ja) | 皮膚外用組成物 | |
JP2004315442A (ja) | 白髪防止・改善剤 | |
JP4683861B2 (ja) | 皮膚外用剤 | |
JP5414137B2 (ja) | ヒアルロニダーゼ活性阻害剤 | |
KR20050098583A (ko) | 옥죽 파우더를 함유하는 피부보습용 화장료 조성물 | |
Somwanshi et al. | Cosmetic Science | |
JP2001158727A (ja) | 皮膚外用剤 | |
JP2016037453A (ja) | 皮膚保湿剤 | |
JP5911293B2 (ja) | 皮膚外用剤 | |
JP2024003819A (ja) | 皮膚化粧料 | |
JPH01121207A (ja) | 美白化粧料 | |
JP2005336134A (ja) | 経皮吸収促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18868820 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019549280 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207014236 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018868820 Country of ref document: EP Effective date: 20200518 |